Fig. 2.

Change in estimated GFR by the CKiDU25 equation (A and B) and CKD-EPI 2021 equation (C and D) during gender-affirming hormone treatment in participants designated male at birth (DMAB) treated with estradiol (A and C) and in participants designated female at birth (DFAB) treated with testosterone (B and D). Estimated GFR (eGFR) was calculated using equations corresponding to the participants’ sex designated at birth (closed squares and solid line) and corresponding to the participants’ gender identity (open squares and dashed lines). Symbols indicate means, and lines indicate standard deviations